An Open-label, Single Arm Clinical Trial of Gallium (68Ga) Edotreotide PET-CT Scan for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors

Trial ID: NCT06091748

Interventional - Phase 3 - Completed

This is a single-arm imaging study using DOTATOC peptide, labelled with the Gallium (68Ga) tracer.

Conditions

• Advanced Gastroenteropancreatic Neuroendocrine Tumor

Interventions

• 68Ga-DOTATOC

Eligibility

Inclusion criteria

• 1. Able and willing to provide a written informed consent;
• 2. 18\~75 years old,male or female；
• 3. ECOG performance status 0 or 1;
• 4. Confirmed or suspicion of GEP-NET.

Exclusion criteria

• 1. Unable to lie flat for the entire imaging duration (e.g. persistent cough, claustrophobia, severe arthritis, etc.), unable to enter the PET/CT device;
• 2. Individuals planning to be pregnant, and lactating women;
• 3. Individuals with concurrent active infections or with unexplained fever \>38.5°C for more than 1 hour during the screening period or prior to administration of investigational medication.

Sponsor

Jiangsu HengRui Medicine Co., Ltd.

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows